BMI thresholds still exist because clinical trials primarily studied patients meeting specific BMI requirements, and FDA indications and insurance policies are generally based on those populations
Tirzepatide is administered as a once-weekly subcutaneous injection, with doses typically starting at 2.5 mg and gradually increasing by 2.5 mg every 4 weeks as tolerated to a maintenance dose ranging from 5 mg to 15 mg, depending on individual response and tolerability
There are several phase 3 trials evaluating GLP-1s for indications, such as metabolic dysfunction-associated steatohepatitis (MASH), prediabetes, Alzheimer's disease, diabetic retinopathy, and osteoarthritis of the knee (in patients with obesity)
For your convenience, we accept most forms of online payment
The bottom line is this: Ozempic works by slowing the passage of everything through the digestive system and that includes any pills taken by mouth